Abstract: Gas generating compositions are formed from a fuel, one or more oxidizers and mica. The gas generant composition of this invention yields solid combustion products and inflating gases having a reduced content of undesirable gases such as NO.sub.x and CO.

Abstract: Gas generating compositions contain a non-azide fuel, phase stabilized ammonium nitrate (PSAN) and silicon. These gas generant compositions yield inflation gases having a reduced content of undesirable gases such as NO.sub.x and CO. The gas generanting compositions preferably contain 5-aminotetrazole at a concentration of 15-30 wt. % as the fuel, an oxidizer system at a concentration of 35-80 wt. % which comprises phase stabilized ammonium nitrate, at least 0.5 wt. % silicon, about 1 wt. % iron oxide and at least one material selected from binders and processing aids. The gas generating compositions are useful for inflating vehicle occupant restraint devices and for pyrotechnically operated fire suppression devices. The high level of gases produced by the compositions of the invention allow for smaller inflators which reduce the costs of production and the saving of weight.

Abstract: The present invention relates to improved non-azide gas generants and methods for their manufacture for use in an automobile gas bag system. This discovery overcomes the problems of moisture and thermal cycling in a non-azide gas generant pellet through the use of at least two fuels selected from guanidine nitrate, nitroguanidine, triaminoguanidine nitrate, diaminoguanidine nitrate and monoguanidine nitrate and an oxidizer system comprising mixtures of strontium nitrate, sodium nitrate and ammonium perchlorate.

Abstract: Process methods are described for combining compounds of mineral nutrients into chemically stable powder mixtures that notably preserve chromium in a soluble form conducive to both absorption and bioavailability. The methods include the compounds of minerals in preferred chemical forms, procedures for treatment of certain compounds to maintain solubility, appropriate sequences for combination of the compounds and other premix ingredients, and blending to provide an adequately homogeneous mixture. The methods provide premixes of minerals that support bioavailable chromium and that exhibit good stability, solubility, odor and color for addition to nutritional products.

Abstract: An autoigniting composition comprising lead thiocyanate Pb(SCN).sub.2 as the fuel, a chlorate as the oxidizer and optionally, a binder and/or a flow agent/thickener are disclosed for use in a vehicle occupant restraint system. The autoignition composition undergoes rapid autoignition at temperatures from approximately 190.degree. to 220.degree. C. thereby allowing the use of aluminum for the gas generator housing. The autoignition compositions of the present invention are safely manufactured by wet blending and may be installed via automation to the interior of the inflator housing. When aluminum housings are used, a barrier material is used to prevent corrosion of the aluminum by the autoignition composition. Optionally the dried autoignition material is coated with a protective substance to prevent water absorption and mechanic abrasion.

Abstract: An airbag inflators employ gas generating compositions formed from a fuel, one or more oxidizers and mica. The gas generant composition employed in the airbag inflators yields solid combustion products and inflating gases having a reduced content of undesirable gases such as NO.sub.x and CO.

Abstract: An autoignition system for use in a gas generator for a vehicle occupant restraint system is disclosed. The autoignition system comprises a globule of an autoignition composition adhering to the interior wall of an inflator housing. The system additionally comprises a barrier layer between the autoignition globule and an aluminum inflator housing. The system further comprises a coating over the globule to reduce abrasion of and water absorption into the autoignition globule. The autoignition system of the present invention is safely manufactured and installed via automation.

Abstract: This invention discloses a method for chemically modifying a pulmonary surfactant protein or polypeptides with various fatty acids. These conjugates are useful in preparing formulations for the treatment of respiratory disease.

Abstract: The primary etiology of antibiotic-associated diarrhea (which may lead to pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs. The present invention involves a non-antibiotic approach to the treatment and/or prevention of C. difficile--associated diseases. A therapeutically effective amount of an indigestible oligosaccharide inhibits the infection of mammals by C. difficile when administered enterally.

Abstract: There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

Abstract: A high quality soy protein isolate with a significant reduction in phytate and aluminum is prepared via ultrafiltration. Defatted soy flour slurry is prepared and adjusted to a pH such that the protein becomes solubilized. The solubilized protein can pass through the ultrafiltration membrane. The ultrafiltration system rejects phytate and aluminum. Once the soluble protein passes through the ultrafiltration system the soy protein isolate is then precipitated from the clear permeate stream by adjusting the pH within the isoelectric range of soy proteins.

Abstract: A method is provided for inhibiting rotavirus infection of human cells by treating the rotavirus with a carrageenan. The most effective agent in inhibiting cellular rotavirus infection is lambda-carrageenan, which may be formulated in a liquid and ingested enterally. A composition containing lambda-carrageenan is an aspect of the invention.

Abstract: A protein containing nutritional supplement that contains from 1 to 10% by weight of whey protein isolate, at least one source of carbohydrate, vitamins, trace minerals and ultra trace minerals and ultra trace minerals. The pH of the liquid nutritional supplement is from about 2.8 to about 3.3 and is essentially devoid of added macro-nutrients and fat. A supplement which is clear and low in viscosity, is produced by preparing (1) an acidified aqueous solution of whey protein isolate having a pH of about 2.8 to about 3.3 and (2) an aqueous solution of carbohydrate; and thereafter combining the two solutions.

Abstract: A powdered beverage concentrate contains a source of calcium, vitamin D, a stabilizing gum such as gum arabic, and vegetable oil. A beverage can be made by reconstituting the beverage concentrate with water, fruit juice, or any other suitable liquid matrix.

Abstract: Prolamine fractions of grain proteins, applied as a single coating in weight ratios of 5 to 100% relative to the active substance being coated, result in the production of a liquid suspension which effectively masks the taste of orally administered drugs which often are extremely bitter. The taste masking is stable over prolonged periods of storage time of the suspension. The prolamine coating does not restrict the immediate bioavailability of the active substance. Prolamine coating is effective in masking the taste of antibiotics, vitamins, dietary fiber, analgesics, enzymes and hormones. Zein, gliadin or a mixture thereof, particularly in combination with between 2.

Abstract: An improved enteral nutritional formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios. The invention also discloses novel methods of production and analytical techniques. This invention also provides a dietary formula that enhances the immune system and alleviates diarrhea.

Abstract: Prolamine fractions of grain proteins, applied as a single coating in weight ratios of 5 to 100% relative to the active substance being coated, result in the production of a liquid suspension which effectively masks the taste of orally administered drugs which often are extremely bitter. The taste masking is stable over prolonged periods of storage time of the suspension. The prolamine coating does not restrict the immediate bioavailability of the active substance. Prolamine coating is effective in masking the taste of antibiotics, vitamins, dietary fiber, analgesics, enzymes and hormones. Zein, gliadin or a mixture thereof, particularly in combination with between 2.

Abstract: The present invention involves a method of preparing a nutritional product in which a powder base containing fats, carbohydrates, vitamins, minerals and trace elements is mixed with specific amino acids to yield several different therapeutic products for use in the nutritional support of infants or toddlers having various inherited metabolic diseases.

Abstract: A method of preventing or treating infection by human rotavirus by administering an enteral nutritional product containing either bovine .kappa.-casein or human .kappa.-casein at a concentration greater than that found in human or bovine milk and sufficient to inhibit infection of mammalian cells by human rotavirus.

Abstract: A method for producing an improved rice flour-based oral rehydration solution using the enzymes cellulase and protease is disclosed. The oral rehydration solution of the invention has low viscosity, low osmolality, and can be ingested through the nipple of a bottle. The oral rehydration product can also be dried into powder form before packaging and reconstituted at the time of use. The product is designed to treat individuals with severe diarrhea brought about by cholera or other causes.